Protein That Causes Blood Vessel Leakage in DR Found
CONNI BERGMANN KOURY, EDITOR-IN-CHIEF
Verteporfin and VEGF-Inhibitor Trial for Neovascular AMD
The DENALI trial is the first large-scale, randomized study of verteporfin and ranibizumab.
LEAH FARR, ASSOCIATE EDITOR
Nonselective Followed by Selective VEGF Blockade May Benefit AMD Patients
Combining nonselective and selective VEGF blockade may provide clinical benefit in the treatment of neovascular age-related macular degeneration.
MARK S. HUGHES, MD
Combined PDT With Intravitreal Bevacizumab Useful for Neovascular AMD
Further investigation with large, controlled trials is warranted.
MANDEEP S. DHALLA, MD, AND GAURAV K. SHAH, MD
Ranibizumab Slows Macular Vision Loss
QUAN DONG NGUYEN, MD, MSc, AND PETER A. CAMPOCHIARO, MD
Intravitreal Bevacizumab in Diabetic Macular Edema Improved Visual Acuity, Retinal Thickness
CHRISTOS HARITOGLOU, MD
Intravitreal Bevacizumab Promising for Neovascularization in Diabetic Retinopathy
RODRIGO JORGE, MD, PhD; INGRID U. SCOTT, MD, MPH; AND ROGÉRIO A. COSTA, MD, PhD
The Importance of Vision-Related Quality of Life in Patients Treated for Neovascular AMD
Patients are not interested in telling an E from an F—they want to be able to differentiate a simple building from a work of art.
TOM S. CHANG, MD, FRCS, MHSc
Intravitreal Injections: Technique and Infection Prophylaxis
Although an intravitreal injection is an extremely safe procedure, it is not completely devoid of risk.
MIGUEL BUSQUETS, MD, FACS
Retinal Pigment Epithelium Tears Linked to Bevacizumab?
The investigators suspect a tissue response rather than an injection-related phenomenon.
ULRICH H. M. SPANDAU, MD, AND JOST B. JONAS, MD
Update on Factor H and Genetic Predisposition to AMD: How Geneticists Understand the Disease
There have been major advances in determining what causes AMD— with the main focus on complement factor H.
RANDO ALLIKMETS, PhD
Risk Factors and Prevention of AMD
The extent to which a patient experiences morbidity as a result of AMD depends in part on how the tissue responds to complications.
ALBERT O. EDWARDS, MD, PHD
No Association of CFH Gene Polymorphism, AMD in Japanese
JUNKO UKA, MD; HIROKI TAMURA, MD; TAKAYUKI KOBAYASHI, MD; AND ATSUSHI MINAMOTO, MD
Defining the Prevalence of AMD and Investigating Racial Differences
Prevalence rates and racial differences in AMD can help guide the development of screening and treatment policies.
SUSAN B. BRESSLER, MD
Clinical Trial Update: AMD
Trial: Genetic Study of Age-Related Macular Degeneration (AMD)
What are the Legal Issues Regarding the Use of Off-label Drugs?
Jointly sponsored by The Dulaney Foundation and Retina Today Release Date: February 2007. Expiration Date: February 28, 2008. This continuing medical education activity is supported by an educational grant from Genentech.
GEORGE A. WILLIAMS, MD